Screener
Collegium Pharmaceutical, Inc. COLL Segment — Interest Income
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Collegium Pharmaceutical, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InvestmentIncomeNet.
The source filing: Collegium Pharmaceutical, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:34 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053851
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Medical expenses | 7,899 | 7,832 | 15,047 | 15,865 |
| Technical operations expenses | 165 | 136 | 415 | 234 |
| Stock-based compensation expense | 14,484 | 10,818 | 25,364 | 22,342 |
| Other segment items(1) | 25,480 | 577 | 31,655 | 2,477 |
| Interest expense | 19,519 | 20,463 | 35,381 | 41,253 |
| Interest income | (2,289) | (2,383) | (5,995) | (4,608) |
| Provision for income taxes | 1,519 | 5,042 | 5,763 | 5,747 |
| Net (loss) income | $(15,051) | $11,983 | $(555) | $14,400 |
Item 1. Condensed Consolidated Financial Statements (Unaudited).
FAQ
- What is Collegium Pharmaceutical, Inc.'s segment — interest income?
- Collegium Pharmaceutical, Inc. (COLL) reported segment — interest income of $2.29M in Q2 2026.
- How has Collegium Pharmaceutical, Inc.'s segment — interest income changed year-over-year?
- Collegium Pharmaceutical, Inc.'s segment — interest income decreased by 3.9% year-over-year, from $2.38M to $2.29M.
- What is the long-term trend for Collegium Pharmaceutical, Inc.'s segment — interest income?
- Over 2 years (2022 to 2024), Collegium Pharmaceutical, Inc.'s segment — interest income has grown at a 265.4% compound annual growth rate (CAGR), from $1.05M to $13.98M.
- What does segment — interest income mean?
- This metric represents the total interest earned on cash balances, short-term investments, and other interest-bearing assets held by the business segment. It reflects the company's ability to generate passive returns on its excess liquidity and working capital. Monitoring this helps investors understand the non-operating income contribution from the segment's treasury management activities.
Ask your AI about Collegium Pharmaceutical, Inc.'s segment — interest income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude